Bartter-like Syndrome In a Patient Receiving Capreomycin For The Treatment Of Multidrug-Resistant Tuberculosis
Bartter syndrome is inherited tubulopathy caused by mutations in several genes causing hypokalemia, hypomagnesemia, hypocalcemia with hypercalciuria, and metabolic alkalosis. Beside from inherited disorder, Bartter syndrome can be caused by the use of aminoglycosides, so it is called Bartter-like syndrome. Hypokalemia has been reported as a side effect of aminoglycosides in many studies, but Bartter-like syndrome due to aminoglycosides has only been reported in a few case reports. We report a 43 years old female patient who developed muscle weakness due to hypokalemia. We found the patient’s laboratory results was consistent with Bartter syndrome. The patient had MDR-TB and received combination therapy with capreomycin for two months. We diagnosed a patient with Bartter-like syndrome due to capreomycin. Following diagnosis, we discontinued capreomycin and started potassium, magnesium and calcium therapy. After electrolyte imbalances improved, capreomycin was given three times per week and the patient was no longer experiencing the same condition.
Al Shibli, A., Narchi, H., 2015. Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. World J. Methodol. 5, 55–61.
Anggraini, D.H., Isbaniah, F., Burhan, E., 2017. Hypokalemia Among Multidrugs Resistant Tuberculosis Patients. Respirology 22, 216–217.
Chothia, M.Y., Esser, J.H., de Vries, N., Davids, M.R., 2018. Bartter-like syndrome caused by kanamycin during therapy for multidrug-resistant Mycobacterium tuberculosis. African J. Nephrol. 21, 16–19.
endTB Consortium, 2018. endTB Clinical and Programmatic Guide for Patient Management with New TB Drugs. Version 4.0.
Hung, C.C., Guh, J.Y., Kuo, M.C., Lai, Y.H., Chen, H.C., 2006. Gentamicin-induced diffuse renal tubular dysfunction. Nephrol. Dial. Transplant. 21, 547–548.
Japp, A.G., Robertson, C., 2013. Macleod’s Clinical Diagnosis. Elsevier, Edinburgh. Mount, D.B., 2018. Fluid and Electrolyte Disturbances, in: Jameson, J.L., Kasper,
D.L., Longo, D.L., Fauci, A.S., Hauser, S.L., Loscalzo, J. (Eds.), Harrison’s Principles of Internal Medicine 20th Edition. Mc Graw-Hill Education, New York, pp. 295–312.
Mount, D.B., 2016. Disorders of Potassium Balance, in: Skorecki, K., Chertow, G.M., Marsden, P.A., Taal, M.W., Yu, A.S.L. (Eds.), Brenner & Rector’s The Kidney 10th Edition. Elsevier, Philadelphia, pp. 559–599.
Pazhayattil, G.S., Shirali, A.C., 2014. Drug-induced impairment of renal function. Int.
J. Nephrol. Renovasc. Dis. 7, 457–68.
Rahmawati, R.N., Pranggono, E.H., Ruslami, R., 2016. Clinical Characteristics and Side Effects of Multidrug Resistant Tuberculosis Therapy at Top Referral Hospital West Java Indonesia. Althea Med. J. 3, 526–32.
Sharma, P., Sahay, R.N., 2017. Unusual Complication of Multidrug Resistant Tuberculosis. Case Reports Nephrol. 2017, 1–3.
Shetty, A.K., Rogers, N.L., Mannick, E.E., Aviles, D.H., 2000. Syndrome of Hypokalemic Metabolic Alkalosis and Hypomagnesemia Associated with Gentamicin Therapy: Case Reports. Clin. Pediatr. (Phila). 39, 529–533.
Shin, S., Furin, J., Alcántara, F., Hyson, A., Joseph, K., Sánchez, E., Rich, M., 2004. Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis. Chest 125, 974–980.
Smogorzewski, M.J., Stubbs, J.R., Yu, A.S.L., 2016. Disorders of Calcium, Magnesium, and Phosphate Balance, in: Skorecki, K., Chertow, G.M., Marsden, P.A., Taal, M.W., Yu, A.S.L. (Eds.), Brenner & Rector’s The Kidney 10th Edition. Elsevier, Philadelphia, pp. 601–634.
Suparyatmo, J.B., AS, B.R., Harsini, Sukma, 2014. Kalium di Multidrug Resistance Tuberculosis dengan Pengobatan Kanamisin. Indones. Hournal Clin. Pathol. Med. Lab. 21, 16–19.
Tang, J., Linas, S.L., 2015. The Patient with Hypokalemia or Hyperkalemia, in: Schrier, R.W. (Ed.), Manual of Nephrology 8th Edition. Wolters Kluwer Health, Philadelphia, pp. 48–60.
World Health Organization, 2019. Global Tuberculosis Report 2019. Geneva, Switzerland.
World Health Organization, 2018. Global Tuberculosis Report 2018. Geneva, Switzerland.
World Health Organization, 2016. WHO treatment guidelines for drugresistant tuberculosis, 2016 update. Geneva, Switzerland.
Copyright (c) Author
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The formal legal aspect of journal publication accessibility refers to Creative Commons Atribution-Share Alike 4.0 (CC BY-SA).